Vinod Balasa
Pediatric Hematology-Oncology · Madera, CANPI 1538190160
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $357,239 of the $508,309 with a category attached, or 70.3%. 26 manufacturers reported payments, led by Sanofi at 53.0% of the total. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 446 payments — averaging $1139.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$270K
- CSL Behring$84K
- Shire North American Group Inc$46K
- Takeda Pharmaceuticals U.S.A., Inc.$38K
- Bioverativ Therapeutics Inc.$34K
- HEMA Biologics, LLC$14K
- plus $23K from 20 others
Across 4 payments — averaging $6112.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- HEMA Biologics, LLC$24K
What the payments were for
- Consulting fees$74,34315%
- Speaking & faculty fees$357,23970%
- Travel & lodging$67,59513%
- Food & beverage$8,9242%
- Education$2070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 172 | $269,520 |
| CSL Behring | 73 | $83,583 |
| Shire North American Group Inc | 52 | $46,020 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $38,056 |
| Bioverativ Therapeutics Inc. | 30 | $33,928 |
| HEMA Biologics, LLC | 22 | $14,081 |
| Novartis | 14 | $12,825 |
| Pfizer | 16 | $6,598 |
| Novo Nordisk | 5 | $1,457 |
| Bayer | 2 | $1,373 |
| Octapharma USA, Inc. | 1 | $300 |
| Gilead | 1 | $118 |
| AstraZeneca | 5 | $108 |
| Alnylam Pharmaceuticals Inc. | 1 | $50 |
| RARE Disease Therapeutics, Inc. | 2 | $49 |
| Pharming Healthcare, Inc. | 2 | $40 |
| Medunik USA Inc. | 1 | $25 |
| Global Blood Therapeutics, Inc. | 1 | $24 |
| Biomarin Pharmaceutical Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Y-mabs Therapeutics, Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTUVIIIO$143,557
- Idelvion$67,518
- ADVATE$62,734
- Afstyla$59,536
- QFITLIA$45,732
- ELOCTATE$36,879
- ALPROLIX$34,648
- SevenFact$13,411
- ADYNOVATE$6,227
- PROMACTA$6,216
- CABLIVI$3,004
- OBIZUR$2,897
- NovoSeven RT$1,360
- Jivi$1,345
- FEIBA$397
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$300
- Yescarta$118
- TASIGNA$116
How this compares
$508,309 in reported general payments places this provider in the 95th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in Madera
- Faisal RazzaqiMadera$77K
- Audrey Green-MurphyMadera$77K
- Philip PizzoPalo Alto$2.6M
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
- Vanessa Salinas-LunaOrange$344K
- Daniel KraftStanford$294K
- Arash MahajerinOrange$249K
- Elysia AlvarezPalo Alto$200K
- Christopher DvorakPalo Alto$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.